A Phase I Study of Lenalidomide plus Chemotherapy with Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients with Acute Myeloid Leukemia

Patients with relapsed AML have a poor prognosis and limited responses to standard chemotherapy. Lenalidomide is an immunomodulatory drug that may modulate anti-tumor immunity. We performed a study to evaluate the safety and tolerability of lenalidomide with mitoxantrone, etoposide and cytarabine (M...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Am J Hematol
Auteurs principaux: DeAngelo, Daniel J., Brunner, Andrew M., Werner, Lillian, Avigan, David, Fathi, Amir T., Sperling, Adam S., Washington, Abigail, Stroopinsky, Dina, Rosenblatt, Jacalyn, McMasters, Malgorzata, Luptakova, Katarina, Wadleigh, Martha, Steensma, David P., Hobbs, Gabriela S., Attar, Eyal C., Amrein, Philip C., Ebert, Benjamin L., Stone, Richard M., Ballen, Karen K.
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6290473/
https://ncbi.nlm.nih.gov/pubmed/29119643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24968
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires